VDAC1-based peptides: Novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia

Cell Death and Disease

Volumn 4, Issue 9, 2013, Pages

  Prezma, T ^a   Shteinfer, A ^a   Admoni, L ^a   Raviv, Z ^a   Sela, I ^a   Levi, I ^b   Shoshan Barmatz, V ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Apoptosis; CLL; Metabolism; Mitochondria; Peptides; VDAC1

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CD19 ANTIGEN; CD5 ANTIGEN; CELL PENETRATING PEPTIDE; CYTOCHROME C; HEXOKINASE; PEPTIDE ANTP LP4; PEPTIDE N TERMINAL ANTP; PROTEIN BCL 2; TRYPTOPHAN; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 1;

AMINO ACID SEQUENCE; ANTIBODY LABELING; APOPTOSIS; ARTICLE; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; CANCER CELL CULTURE; CELL DEATH; CELL ENERGY; CELL KILLING; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA FRAGMENTATION; ENERGY METABOLISM; ENERGY YIELD; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE TRIPHOSPHATE; AGED; AMINO ACID SEQUENCE; APOPTOSIS; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; CYTOCHROMES C; FEMALE; HEXOKINASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN MULTIMERIZATION; VOLTAGE-DEPENDENT ANION CHANNEL 1;

EID: 84884994343     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.316     Document Type: Article

References (53)

1. Montserrat E, Moreno C. Chronic lymphocytic leukaemia: A short overview. Ann Oncol 2008; 19(Suppl 7): Vii320-vii325
2. Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2004; 1: 163-183
3. Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466-1471
4. Gottardi D, Alfarano A, De Leo AM, Stacchini A, Aragno M, Rigo A et al. In leukaemic CD5 B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis. Br J Haematol 1996; 94: 612-618
5. Schmitt B, Wendtner CM, Bergmann M, Busch R, Franke A, Pasold R et al. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin Lymphoma 2002; 3: 26-35
6. Christian BA, Lin TS. Antibody therapy for chronic lymphocytic leukemia. Semin Hematol 2008; 45: 95-103
7. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674
8. Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: Cancer's stygian link to the 'Warburg Effect' and a pivotal target for effective therapy. Semin Cancer Biol 2009; 19: 17-24
9. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567-1574
10. Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N, Arbel N. VDAC a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med 2010; 31: 227-285
11. Shoshan-Barmatz V, Keinan N, Abu-Hamad S, Tyomkin D, Aram L. Apoptosis is regulated by the VDAC1 N-Terminal region and by VDAC oligomerization: Release of cytochrome c, AIF and Smac/Diablo. Biochim Biophys Acta 2010; 1797: 1281-1291
12. Zaid H, Abu-Hamad S, Israelson A, Nathan I, Shoshan-Barmatz V. The voltage-dependent anion channel-1 modulates apoptotic cell death. Cell Death Differ 2005; 12: 751-760
13. Abu-Hamad S, Arbel N, Calo D, Arzoine L, Israelson A, Keinan N et al. The VDAC1 N-Terminus is essential both for apoptosis and the protective effect of anti-Apoptotic proteins. J Cell Sci 2009; 122(Pt 11): 1906-1916
14. Arbel N, Ben-Hail D, Shoshan-Barmatz V. Mediation of the anti-Apoptotic activity of BCLXL upon interaction with VDAC1. J Biol Chem 2012; 287: 23152-23161
15. Arbel N, Shoshan-Barmatz V. Voltage-dependent anion channel 1-based peptides interact with bcl-2 to prevent antiapoptotic activity. J Biol Chem 2010; 285: 6053-6062
16. Abu-Hamad S, Zaid H, Israelson A, Nahon E, Shoshan-Barmatz V. Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltagedependent anion channel-1: Mapping the site of binding. J Biol Chem 2008; 283: 13482-13490
17. Arzoine L, Zilberberg N, Ben-Romano R, Shoshan-Barmatz V. Voltage-dependent anion channel 1-based peptides interact with hexokinase to prevent its anti-Apoptotic activity. J Biol Chem 2009; 284: 3946-3955
18. Grobholz R, Zentgraf H, Kohrmann KU, Bleyl U. Bax Bcl-2, fas and Fas-L antigen expression in human seminoma: Correlation with the apoptotic index. Apmis 2002; 110: 724-732
19. Schimmer AD, Munk-Pedersen I, Minden MD, Reed JC. Bcl-2 and apoptosis in chronic lymphocytic leukemia. Curr Treat Options Oncol 2003; 4: 211-218
20. Abu-Hamad S, Sivan S, Shoshan-Barmatz V. The expression level of the voltagedependent anion channel controls life and death of the cell. Proc Natl Acad Sci USA 2006; 103: 5787-5792
21. Cochran AG, Tong RT, Starovasnik MA, Park EJ, McDowell RS, Theaker JE et al. A minimal peptide scaffold for beta-Turn display: Optimizing a strand position in disulfidecyclized beta-hairpins. J Am Chem Soc 2001; 123: 625-632
22. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D et al. MEC1 and MEC2: Two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999; 23: 127-136
23. Admoni L, Shteinfer A, Prezma T, Arbel N, Melkov A et al. VDAC1-based peptides induce selective death of B-chronic lymphocytic leukemia cells. Submitted
24. Keinan N, Tyomkin D, Shoshan-Barmatz V. Oligomerization of the mitochondrial protein voltage-dependent anion channel is coupled to the induction of apoptosis. Mol Cell Biol 2010; 30: 5698-5709
25. Shoshan-Barmatz V, Mizrachi D. VDAC1: From structure to cancer therapy. Front Oncol 2012; 2: 164
26. Ferraro E, Pulicati A, Cencioni MT, Cozzolino M, Francesca Navoni F, di Martino S et al. Apoptosome-deficient cells lose cytochrome c through proteasomal degradation but survive by autophagy-dependent glycolysis. Mol Biol Cell 2008; 19: 3576-3588
27. Daniels TR, Bernabeu E, Rodriguez JA, Patel S, Kozman M, Chiappetta DA et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012; 1820: 291-317
28. Smilevska T, Stamatopoulos K, Samara M, Belessi C, Tsompanakou A, Paterakis G et al. Transferrin receptor-1 and 2 expression in chronic lymphocytic leukemia. Leuk Res 2006; 30: 183-189
29. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: Back to basics. Adv Drug Deliv Rev 2005; 57: 559-577
30. Moede T, Leibiger B, Pour HG, Berggren P, Leibiger IB. Identification of a nuclear localization signal, RRMKWKK, in the homeodomain transcription factor PDX-1. FEBS Lett 1999; 461: 229-234
31. Cymer F, Veerappan A, Schneider D. Transmembrane helix-helix interactions are modulated by the sequence context and by lipid bilayer properties. Biochim Biophys Acta 1818 963-973
32. Ospina A, Lagunas-Martinez A, Pardo J, Carrodeguas JA. Protein oligomerization mediated by the transmembrane carboxyl terminal domain of Bcl-XL. FEBS Lett 2011; 585: 2935-2942
33. Lee JH, Engler JA, Collawn JF, Moore BA. Receptor mediated uptake of peptides that bind the human transferrin receptor. Eur J Biochem 2001; 268: 2004-2012
34. Han L, Huang R, Li J, Liu S, Huang S, Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials 2011; 32: 1242-1252
35. Han L, Li J, Huang S, Huang R, Liu S, Hu X et al. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-Targeted T1 magnetic resonance imaging contrast agent. Biomaterials 2011; 32: 2989-2998
36. Oh S, Kim BJ, Singh NP, Lai H, Sasaki T. Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett 2009; 274: 33-39
37. Ferreira LM. Cancer metabolism: TheWarburg effect today. ExpMol Pathol 2010; 89: 372-380
38. Kaelin WG Jr., Thompson CB. Q&A: Cancer: Clues from cell metabolism. Nature 2010; 465: 562-564
39. Mathupala SP, Ko YH, Pedersen PL., Hexokinase II. Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006; 25: 4777-4786
40. Wenner CE. Cell signaling and cancer-possible targets for therapy. J Cell Physiol 2010; 223: 299-308
41. Shulga N, Wilson-Smith R, Pastorino JG. Hexokinase II detachment from the mitochondria potentiates cisplatin induced cytotoxicity through a caspase-2 dependent mechanism. Cell Cycle 2009; 8: 3355-3364
42. Kraaijenhagen RJ, de Gast GC, van der Heijden MC, Streefkerk M, Gmelig-Meyling FH, Rijksen G et al. Isozyme distribution of hexokinase, phosphofructokinase and pyruvate kinase in lymphocytes from patients with chronic lymphocytic leukemia. Clin Chim Acta 1982; 124: 91-101
43. Azoulay-Zohar H, Israelson A, Abu-Hamad S, Shoshan-Barmatz V. In self-defence: Hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 2004; 377(Pt 2): 347-355
44. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 4079-4088
45. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-5623
46. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007; 48: 2412-2417
47. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008; 22: 2048-2053
48. Advani PP, Paulus A, Masood A, Sher T, Chanan-Khan A. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol 2011; 7: 765-774
49. Tan W, Loke YH, Stein CA, Miller P, Colombini M. Phosphorothioate oligonucleotides block the VDAC channel. Biophys J 2007; 93: 1184-1191
50. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009; 113: 4403-4413
51. Merino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong C et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood 2012; 119: 5807-5816
52. Raucher D, Moktan S, Massodi I, Bidwell GL 3rd. Therapeutic peptides for cancer therapy. Part II-cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin Drug Deliv 2009; 6: 1049-1064
53. Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today May 2013; S1359-6446: 00157-00158